

IN THE CLAIMS:

Please amend claims 1, 3, and 4 as set forth below. Each of the claims pending in the application are provided below for clarity.

Claim 1 (Currently Amended): A sustained release oral dosage form comprising a liquid, self-emulsifying antiviral drug formulation comprising an amount of an antiviral drug sufficient to provide a therapeutically effective dose of the antiviral drug over a period of at least four hours, wherein the antiviral drug in solubilized form accounts for up to 60 wt% of [a solubilized antiviral drug, wherein] the liquid, self-emulsifying antiviral drug formulation and the dosage form is configured to administer a therapeutically effective dose of said antiviral drug over a period of at least 4 hours after oral administration with no more than 30% by weight of said liquid, self-emulsifying antiviral drug formulation being released within the first 1 hour after oral administration.

Claim 3 (Currently Amended): A sustained release oral dosage form comprising a liquid, self-emulsifying antiviral drug formulation comprising an amount of an antiviral drug sufficient to provide a therapeutically effective dose of the antiviral drug over a period of at least 12 hours, wherein the antiviral drug in solubilized form accounts for up to 60 wt% of [a solubilized antiviral drug, wherein] the liquid, self-emulsifying antiviral drug formulation and the dosage form is configured to administer a therapeutically effective dose of said antiviral drug over a period of at least 12 hours after oral administration with no more than 30% by weight of said liquid, self-emulsifying antiviral drug formulation being released within the first 4 hours after oral administration.

Claim 4 (Amended Currently): A sustained release oral dosage form comprising a liquid, self-emulsifying antiviral drug formulation comprising an amount of an antiviral drug sufficient to provide a therapeutically effective dose of the antiviral drug over a period of at least 24 hours, wherein the antiviral drug in solubilized form accounts for up to 60 wt% of [a solubilized antiviral drug, wherein] the liquid, self-emulsifying antiviral drug formulation and the dosage form is configured to administer a therapeutically effective dose of said antiviral drug over a period of 24 hours after oral administration with no more than 30% by weight of said liquid, self-emulsifying antiviral drug formulation being released within the first 12 hours after oral administration.